Introduction: This retrospective follow-up study evaluates patient outcomes and treatment costs in two cohorts of incident NSCLC patients recorded in the population-based cancer registry of the Veneto Region in 2017 and 2019. Methods: This study examines two cohorts of incident NSCLC patients recorded by the Regional Veneto cancer registry in 2017 (493 patients) and 2019 (557 patients). Cancer patients were followed for three years after diagnosis to assess the disease’s outcomes and analyze the overall treatment-related costs. Overall survival and cancer-specific mortality were evaluated using Cox regression models. The log-transformed overall treatment costs for the 3 years following diagnosis were analyzed using linear regression. Results: The overall mortality risk significantly lowered in the 2019 cohort (HR 0.84; 95% CI 0.72–0.98,p= 0.024). Stage III patients were not associated with a significant overall survival rate (HR 0.71; 95% CI 0.50–1.02;p= 0.065) but were associated with significantly higher cancer-specific survival (HR 0.61; 95% CI 0.41–0.91;p= 0.015). Overall, the 2019 cohort showed significantly higher costs (coefficient 0.16; 95% CI 0.02–0.30,p= 0.025), particularly as a result of increases in the costs of drug administration, outpatient services, and medical devices. However, during the same 3-year follow-up period, this cohort featured lower average costs for hospice care and hospitalizations. Conclusions: These results revealed notable differences in clinical outcomes and patient-related costs in incident NSCLCs in 2017 and 2019. The study highlights the importance of monitoring clinical outcomes and management costs in real-world oncology practice.
引言：本回顾性随访研究基于威尼托大区人群癌症登记系统，对2017年与2019年两个新发非小细胞肺癌（NSCLC）患者队列的治疗结果及医疗成本进行评估。方法：研究纳入威尼托大区癌症登记系统记录的2017年（493例）与2019年（557例）两个新发NSCLC患者队列。对确诊后三年内的患者进行随访，评估疾病结局并分析总体治疗相关费用。采用Cox回归模型评估总生存期与癌症特异性死亡率，通过线性回归分析确诊后三年内对数转换的总体治疗费用。结果：2019年队列总体死亡风险显著降低（风险比0.84；95%置信区间0.72–0.98，p=0.024）。III期患者虽未显示显著的总生存期改善（风险比0.71；95%置信区间0.50–1.02；p=0.065），但其癌症特异性生存率显著提高（风险比0.61；95%置信区间0.41–0.91；p=0.015）。总体而言，2019年队列治疗费用显著增加（系数0.16；95%置信区间0.02–0.30；p=0.025），主要源于药物输注、门诊服务及医疗器械费用的增长。但在三年随访期内，该队列的临终关怀与住院平均费用较低。结论：研究结果揭示了2017年与2019年新发NSCLC患者在临床结局及医疗成本方面的显著差异，凸显了在真实世界肿瘤学实践中持续监测临床结局与管理成本的重要性。
NON-SMALL-CELL LUNG CANCER: Real-World Population-Based Cohorts’ Study
肿瘤(癌症)患者之家